Fremanezumab
Monoclonal antibody for migraine prevention
| Fremanezumab | |
|---|---|
| |
| INN | |
| Drug class | Monoclonal antibody |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Fremanezumab, sold under the brand name Ajovy, is a monoclonal antibody used for the prevention of migraines. It is specifically designed to target and inhibit the activity of the calcitonin gene-related peptide (CGRP), a molecule involved in migraine pathophysiology.
Mechanism of Action[edit]
Fremanezumab works by binding to the CGRP ligand, thereby preventing it from interacting with its receptor. CGRP is a neuropeptide that plays a crucial role in the transmission of pain and the development of migraine headaches. By inhibiting CGRP, fremanezumab reduces the frequency and severity of migraine attacks.
Clinical Use[edit]
Fremanezumab is indicated for the preventive treatment of migraine in adults. It is administered via subcutaneous injection and can be given either as a monthly dose or a quarterly dose, depending on the patient's needs and the prescribing physician's recommendation.
Side Effects[edit]
Common side effects of fremanezumab include injection site reactions, such as pain, redness, and swelling. Some patients may also experience hypersensitivity reactions. It is important for patients to discuss any adverse effects with their healthcare provider.
Development and Approval[edit]
Fremanezumab was developed by Teva Pharmaceuticals and received approval from the U.S. Food and Drug Administration (FDA) in September 2018. It was one of the first CGRP inhibitors to be approved for migraine prevention, marking a significant advancement in the treatment of this condition.
Related Pages[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
- Budget GLP-1 shots
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
